Dyslipidemia – the known unknown

Česká verzia

Authors: Martin Šatný
Authors place of work: Centrum preventivní kardiologie, 3. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in the journal: Vnitř Lék 2023; 69(5): 305-310
Category:
doi: https://doi.org/10.36290/vnl.2023.060

Summary

Dyslipidemia (DLP) is the most important risk factor for atherosclerotic cardiovascular disease (ASCVD) and, in the context of severe hypertriglyceridemia (TG > 10 mmol/l), a risk factor for the development of acute pancreatitis. The prevalence of DLP is very high, but their control, especially among the patients at highest risk, is often inadequate. When diagnosing DLP, we should always exclude its possible secondary aetiology (e.g. DLP in the context of hypothyroidism, diabetes, ...). Based on the assessment of the overall CV risk (according to SCORE2/SCORE2-OP or according to the comorbidities of the individual), target values for blood lipids, especially LDL-cholesterol, are determined according to the risk category. The basis of the management of DLP in the prevention of ASCVD is dietary and regimen measures, followed by adequate lipid-lowering therapy in indicated cases. As of April 2023, the portfolio of lipid-lowering medication has been expanded to include inclisiran (small interfering RNA against proprotein convertase subtilisin/kexin type 9 (PCSK9)), which is administered directly in cardiologists‘ and internists‘ outpatient clinics, ensuring 100% adherence. In severe hypertriglyceridaemia, fibrate monotherapy may be indicated in addition to dietary and regimen measures; if this treatment fails, some patients may be offered lomitapide, volanesorsen or evinacumab as part of clinical trials or specific treatment programmes if very strict indication criteria are met.

Keywords:

dyslipidemia – cardiovascular risk – acute pancreatitis – atherosclerotic cardiovascular disease – inclisiran

Zdroje

Sanin V, Koenig W. Therapie der Hypercholesterinämie in der Primärprävention. DMW Deutsche Medizinische Wochenschrift [online]. 2019;144(05):322-328. doi: 10.1055/a0657-1668.
Cífková R, Bruthans J, Wolhlfahrt P, et al. (The prevalence of major cardiovascular risk factors in the Czech population in 2015-2018. The Czech post-MONICA study). Cor et Vasa. 2020;62(1):6-16. doi: 10.33678/cor.2020.010.
Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937-952. doi: 10.1016/S0140-6736(04)17018-9.
Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016 Oct;27(5):473-83. doi: 10.1097/MOL.0000000000000330.
Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl. 2010 Jun;11(1):55-60. doi: 10.1016/j.atherosclerosissup.2010. 03. 004.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2019 DOI: 10.1093/eurheartj/ehz455.
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal [online]. 2021;42 (34):3227-3337. doi:10.1093/eurheartj/ehab484.
Šatný M, Vrablík M. Sekundární dyslipidemie. AtheroRev 2017;2(3):162-168.
Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation. 1965 Mar;31:321-7. doi: 10.1161/01.cir.31. 3. 321.
Zemřelí 2020. Ústav pro zdravotnické informace a statistiku 2021. ISSN 1210-9967.
Kotseva K. The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention. Cardiovascular Diagnosis and Therapy. 2017;633-639. doi: 10.21037/cdt.2017. 04. 06. 12.
Šatný M, Vrablík M, Tůmová E, et al. Profil pacientů s nekontrolovanou arteriální hypertenzí a/nebo dyslipidemií v primární péči v Česku – studie LipitenCliDec: výsledky 1. fáze, AtheroRev. 2020;5(1):47-52.
Šatný M, Tůmová E, Vrablík M. LIPIcontrol: daří se zlepšovat úroveň kontroly hlavních rizikových faktorů kardiovaskulárních onemocnění v každodenní praxi?. Hypertenze KV Prevence. 2018;7(1):15-21.
Šatný M, Tůmová E, Vrablík M. Srovnání profilu a léčby pacientů s nekontrolovanou arteriální hypertenzí a/nebo dyslipidemií v péči specialistů a v primární péči v Česku: srovnání výsledků studie LipitenCliDec 1 a LipitenCliDec 2. AtheroRev. 2021;6(3):154-162.
Šatný M, Vrablík M. LIPIcontrol 2 aneb co se změnilo po 3 letech. AtheroRev 2020;5(3):185-190.
Vrablík M. Farmakoterapie dyslipidemie. 2. rozšířené vydání. Praha: Maxdorf, 2016. Farmakoterapie pro praxi. ISBN 978-80-7345-503-3.
Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547-563.
Schwartz EA, Reaven PD. Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochim Biophys Acta. 2012;1821:858-866.
Simha V. Management of hypertriglyceridemia. BMJ. ISSN 1756-1833. doi:10.1136/ bmj.m3109.
Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. European Heart Journal. 2020;41(1):99-109c. doi:10.1093/eurheartj/ehz785.
Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies–a consensus statement from the European Atherosclerosis Society. European Heart Journal. 2021;42(47):4791-4806. doi:10.1093/eurheartj/ehab551.
Pedersen SB, Langsted SB, Nordestgaard BG. Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. JAMA Internal Medicine. 2016;176(12). doi:10.1001/ jamainternmed.2016.6875.
He WH, Zhu Y, Zhu Y, et al. Comparison of severity and clinical outcomes between hypertriglyceridemic pancreatitis and acute pancreatitis due to other causes. Zhonghua Yi Xue Za Zhi. 2016 Aug 23;96(32):2569-72. doi: 10.3760/cma.j.issn.0376-2491.2016. 32. 011.
Graham MJ, Viney N, Crooke RM, et al. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016 Mar;57(3):340-51. doi: 10.1194/jlr.R052258.
Ezetimib (SPC). Souhrn informací o přípravku. Available from: www.sukl.cz.
Alirocumab (SPC). Souhrn informací o přípravku. Available from: www.sukl.cz.
Evolocumab (SPC). Souhrn informací o přípravku. Available from: www.sukl.cz.
Altschmiedová T, Todorovová V, Šnejdrlová M, et al. PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology. Curr Atheroscler Rep. 2022 May;24(5):357-363. doi: 10.1007/s11883-022-01008-8.
Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664.
Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031.
Inclisiran (SPC). Souhrn informací o přípravku. Available from: www.sukl.cz.
Frampton JE. Inclisiran: A Review in Hypercholesterolemia. Am J Cardiovasc Drugs. 2023 Mar;23(2):219-230. doi: 10.1007/s40256-023-00568-7.